Clinical Trials Browser

Fibromatosis, Gingival, 2 × Thoracic × Clear all

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT05919537 2025-04-18

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Phase 1 Active not recruiting

68 enrolled

GastrointestinalThoracic

Fibromatosis, Gingival, 2, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Pancreatic Neoplasms

NCT04383210 2025-04-03

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Phase 2 Terminated

54 enrolled 11 charts

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Fibromatosis, Gingival, 2, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Uterine Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02387216 2021-10-12

SHERLOC

Phase 2 Terminated

153 enrolled 19 charts

Thoracic

Fibromatosis, Gingival, 2, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

Clinical Trials

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

SHERLOC